

Press Coverage | November 11, 2024

Life Sciences M&A Set to Boom, Litigation to Remain Steady Under New Trump Admin

RELATED PROFESSIONALS

Deborah L. Spranger | Andrew P. Zappia

Debbie Spranger and Andrew Zappia, partners with Troutman Pepper, were quoted in the November 11, 2024 *The Legal Intelligencer* article, “[Life Sciences M&A Set to Boom, Litigation to Remain Steady Under New Trump Admin.](#)”

“M&A has been down in 2024. That’s not a secret. But I’m already receiving phone calls from companies looking to get back into the M&A market in a big way now that the elections results have been announced,” said Troutman Pepper Hamilton & Sanders health care and life sciences co-chair Deborah Spranger. “I got a call from a client looking to not only increase the volume of their M&A work but also increase the size of the deals they’re doing. ... The demand for transactional work at firms across the country is going to increase significantly in 2025.”

...

“We see a fairly consistent amount of litigation in the pharmaceutical space and ... the election result isn’t going to drive change one way or the other,” said Troutman Pepper health sciences intellectual property leader Andrew Zappia. “The one thing that is pretty constant in the legal business is that changes in the regulatory environment, either way, usually leads to more work for lawyers. Changes in whatever political direction usually mean that clients have to react and need assistance.”

RELATED INDUSTRIES + PRACTICES

- [Health Care + Life Sciences](#)
- [Health Care Transactions](#)
- [Life Sciences Transactions](#)